Market Overview:
The global diabetic nephropathy market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetic nephropathy treatment. Based on type, the market is segmented into ACE inhibitors, ARBs, diuretics, calcium channel blockers (CCBs), renin inhibitors, connective tissue growth factor (CTGF) inhibitors, antioxidant inflammation modulators (AIMs), monocyte chemoattractant protein (MCP) inhibitors and endothelin-A receptor(ETAR) antagonist. The ACE inhibitor segment is expected to dominate the global diabetic nephropathy market during the forecast period owing to its high efficacy and safety profile. Based on application, hospitals are estimated to account for a major share of the global diabetic nephropathy market during 2018-2030 owing to increasing number of patients with diabetes mellitus seeking hospital care for management of their disease condition.
Product Definition:
Diabetic nephropathy is a kidney disease that results from damage to the tiny blood vessels in the kidneys caused by diabetes. Diabetes is the leading cause of kidney failure in developed countries.
ACE Inhibitors:
ACE inhibitors are a class of drugs that inhibit the activity of ACE (angiotensin-converting enzyme) and thus decrease the formation of angiotensin II. The inhibition results in less volume formation and blood pressure elevation through reduced renal production of renin, vasopressors, and aldosterone.
ARBs:
ARBs are angiotensin II receptor blockers. They are used to treat the symptoms of Diabetic Nephropathy (DN) and prevent its progression. ARBs lower blood pressure by blocking the action of a chemical messenger known as renin which is produced in response to hypoglycemia or low blood sugar.
The global market for ARBs was valued at USD 2,708 million in 2015.
Application Insights:
Diabetic nephropathy application segmentation includes hospitals, cancer research institutes, and diagnostic laboratories. Hospitals were the largest revenue generating centers in 2017 owing to the large number of patients suffering from diabetic kidney diseases and associated conditions. The hospital segment is anticipated to maintain its dominance over the forecast period due to a high prevalence of diabetes-related kidney diseases coupled with advanced healthcare facilities in major countries such as U.S., China, India, Brazil etc.
The cancer research institutes are expected to be one of the fastest growing segments during the forecast period owing to increasing R&D initiatives for developing effective treatment options for diabetic nephropathy along with other chronic renal diseases (C RDs).
Regional Analysis:
North America dominated the global diabetic nephropathy market in 2016. This can be attributed to favorable reimbursement policies, high healthcare expenditure and availability of effective treatment for DNI. The region is expected to maintain its dominance throughout the forecast period owing to increasing R&D investments by pharmaceutical companies and rising prevalence of diabetes in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to improving economic conditions, growing awareness about early diagnosis & treatment options for DNI, increase in disposable income levels coupled with an increase in healthcare spending by governments & private organizations.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The increasing prevalence of diabetes mellitus is the major growth driver for the diabetic nephropathy market. According to the World Health Organization (WHO), in 2015, around 415 million people were living with diabetes and this number is expected to increase to 642 million by 2030. This will lead to an increase in the incidence of diabetic nephropathy.
- Rising awareness about diabetic nephropathy: There is a growing awareness among people about diabetic nephropathy and its complications. This is leading to an increased demand for diagnosis and treatment of this condition.
- Growing aging population: The global aging population is another key growth driver for the diabetic nephropathy market, as elderly individuals are more susceptible to developing this condition than younger individuals are.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Nephropathy Market Research Report
By Type
ACE Inhibitors, ARBs, Diuretics, Calcium Channel Blockers(CCBs), Renin Inhibitors, Connective Tissue Growth Factor (CTGF) Inhibitors, Antioxidant Inflammation Modulators(AIMs), Monocyte Chemoattractant Protein (MCP)Inhibitors, Endothelin-A Receptor(ETAR)Antagonist, G Protein-Coupled Receptors (GPCRs)
By Application
Hospitals, Cancer Research Institutes, Diagnostic Labs
By Companies
Novartis, Merck, Pfizer, Abbott Laboratories, Sanofi, Eli Lilly, AbbVie, Reata Pharmaceuticals, Bayer, Mitsubishi Tanabe Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
179
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Nephropathy Market Report Segments:
The global Diabetic Nephropathy market is segmented on the basis of:
Types
ACE Inhibitors, ARBs, Diuretics, Calcium Channel Blockers(CCBs), Renin Inhibitors, Connective Tissue Growth Factor (CTGF) Inhibitors, Antioxidant Inflammation Modulators(AIMs), Monocyte Chemoattractant Protein (MCP)Inhibitors, Endothelin-A Receptor(ETAR)Antagonist, G Protein-Coupled Receptors (GPCRs)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Institutes, Diagnostic Labs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Merck
- Pfizer
- Abbott Laboratories
- Sanofi
- Eli Lilly
- AbbVie
- Reata Pharmaceuticals
- Bayer
- Mitsubishi Tanabe Pharma
Highlights of The Diabetic Nephropathy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACE Inhibitors
- ARBs
- Diuretics
- Calcium Channel Blockers(CCBs)
- Renin Inhibitors
- Connective Tissue Growth Factor (CTGF) Inhibitors
- Antioxidant Inflammation Modulators(AIMs)
- Monocyte Chemoattractant Protein (MCP)Inhibitors
- Endothelin-A Receptor(ETAR)Antagonist
- G Protein-Coupled Receptors (GPCRs)
- By Application:
- Hospitals
- Cancer Research Institutes
- Diagnostic Labs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Nephropathy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic nephropathy is a kidney disease that develops in people with diabetes mellitus, a condition in which the body doesn't produce or properly use insulin. Diabetes causes damage to blood vessels throughout the body, including those in the kidneys. As blood flow to the kidneys decreases, they can become damaged and eventually fail. Diabetic nephropathy is one of the most common types of kidney disease and can lead to renal failure if not treated properly.
Some of the major players in the diabetic nephropathy market are Novartis, Merck, Pfizer, Abbott Laboratories, Sanofi, Eli Lilly, AbbVie, Reata Pharmaceuticals, Bayer, Mitsubishi Tanabe Pharma.
The diabetic nephropathy market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Nephropathy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Nephropathy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Nephropathy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Nephropathy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Nephropathy Market Size & Forecast, 2018-2028
4.5.1 Diabetic Nephropathy Market Size and Y-o-Y Growth
4.5.2 Diabetic Nephropathy Market Absolute $ Opportunity
Chapter 5 Global Diabetic Nephropathy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Nephropathy Market Size Forecast by Type
5.2.1 ACE Inhibitors
5.2.2 ARBs
5.2.3 Diuretics
5.2.4 Calcium Channel Blockers(CCBs)
5.2.5 Renin Inhibitors
5.2.6 Connective Tissue Growth Factor (CTGF) Inhibitors
5.2.7 Antioxidant Inflammation Modulators(AIMs)
5.2.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
5.2.9 Endothelin-A Receptor(ETAR)Antagonist
5.2.10 G Protein-Coupled Receptors (GPCRs)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Nephropathy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Nephropathy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Institutes
6.2.3 Diagnostic Labs
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Nephropathy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Nephropathy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Nephropathy Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Nephropathy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Nephropathy Market Size Forecast by Type
9.6.1 ACE Inhibitors
9.6.2 ARBs
9.6.3 Diuretics
9.6.4 Calcium Channel Blockers(CCBs)
9.6.5 Renin Inhibitors
9.6.6 Connective Tissue Growth Factor (CTGF) Inhibitors
9.6.7 Antioxidant Inflammation Modulators(AIMs)
9.6.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
9.6.9 Endothelin-A Receptor(ETAR)Antagonist
9.6.10 G Protein-Coupled Receptors (GPCRs)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Nephropathy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Institutes
9.10.3 Diagnostic Labs
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Nephropathy Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Nephropathy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Nephropathy Market Size Forecast by Type
10.6.1 ACE Inhibitors
10.6.2 ARBs
10.6.3 Diuretics
10.6.4 Calcium Channel Blockers(CCBs)
10.6.5 Renin Inhibitors
10.6.6 Connective Tissue Growth Factor (CTGF) Inhibitors
10.6.7 Antioxidant Inflammation Modulators(AIMs)
10.6.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
10.6.9 Endothelin-A Receptor(ETAR)Antagonist
10.6.10 G Protein-Coupled Receptors (GPCRs)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Nephropathy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Institutes
10.10.3 Diagnostic Labs
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Nephropathy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Nephropathy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Nephropathy Market Size Forecast by Type
11.6.1 ACE Inhibitors
11.6.2 ARBs
11.6.3 Diuretics
11.6.4 Calcium Channel Blockers(CCBs)
11.6.5 Renin Inhibitors
11.6.6 Connective Tissue Growth Factor (CTGF) Inhibitors
11.6.7 Antioxidant Inflammation Modulators(AIMs)
11.6.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
11.6.9 Endothelin-A Receptor(ETAR)Antagonist
11.6.10 G Protein-Coupled Receptors (GPCRs)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Nephropathy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Institutes
11.10.3 Diagnostic Labs
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Nephropathy Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Nephropathy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Nephropathy Market Size Forecast by Type
12.6.1 ACE Inhibitors
12.6.2 ARBs
12.6.3 Diuretics
12.6.4 Calcium Channel Blockers(CCBs)
12.6.5 Renin Inhibitors
12.6.6 Connective Tissue Growth Factor (CTGF) Inhibitors
12.6.7 Antioxidant Inflammation Modulators(AIMs)
12.6.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
12.6.9 Endothelin-A Receptor(ETAR)Antagonist
12.6.10 G Protein-Coupled Receptors (GPCRs)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Nephropathy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Institutes
12.10.3 Diagnostic Labs
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Nephropathy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Nephropathy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Nephropathy Market Size Forecast by Type
13.6.1 ACE Inhibitors
13.6.2 ARBs
13.6.3 Diuretics
13.6.4 Calcium Channel Blockers(CCBs)
13.6.5 Renin Inhibitors
13.6.6 Connective Tissue Growth Factor (CTGF) Inhibitors
13.6.7 Antioxidant Inflammation Modulators(AIMs)
13.6.8 Monocyte Chemoattractant Protein (MCP)Inhibitors
13.6.9 Endothelin-A Receptor(ETAR)Antagonist
13.6.10 G Protein-Coupled Receptors (GPCRs)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Nephropathy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Institutes
13.10.3 Diagnostic Labs
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Nephropathy Market: Competitive Dashboard
14.2 Global Diabetic Nephropathy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Merck
14.3.3 Pfizer
14.3.4 Abbott Laboratories
14.3.5 Sanofi
14.3.6 Eli Lilly
14.3.7 AbbVie
14.3.8 Reata Pharmaceuticals
14.3.9 Bayer
14.3.10 Mitsubishi Tanabe Pharma
